Three outpatients who fulfilled full DSM-IV diagnostic criteria for premenstrual dysphoric disorder (PDD) were successfully treated with intermittent (luteal phase) nefazodone. They received the medication at low doses of up to 100 mg/day (50 mg b.i.d.), for 2 weeks through the luteal phase of the menstrual cycle only. All the patients reported a marked symptomatic improvement, including full remission of their emotional symptoms, and two achieved in addition full remission of their somatic symptoms. Side-effects reported during the treatment were mild. The use of luteal phase nefazodone seems to be a promising treatment strategy for the management of PDD. It offers advantages over daily dosing throughout the menstrual cycle, such as reduced incidence and severity of side-effects, and avoids the stigma that may accompany the continuous use of psychopharmacological treatment, with the advantage that compliance may be improved.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn.American Psychiatric Association, Washington, DC
2.
Ashby C R Jr, Carr L A, Cook C L, Steptoe M M, Franks D D (1988) Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry24: 225–233
3.
Bancroft J, Cook A, Davidson D, Bennie J, Goodwin G M. (1991) Blunting of neuroendocrine responses to infusion of L-tryptophan in women with premenstrual mood changesPsychol Med21: 305–312
4.
Davis R, Whittington R, Bryson H M (1997) Nefazodone. A review of it pharmacology and clinical efficacy in the management of major depression. Drugs53: 608–636
5.
Freeman E W, Rickels K, Sondheimer S J (1996) Fluvoxamine for premenstrual dysphoric disorder: a pilot study. J Clin Psychiatry57 (Suppl. 8): 56–59
6.
Haskett R F, Abplanalp J M (1983) Premenstrual tension syndrome: diagnostic criteria and selection of research subjects. Psychiatry Res9: 125–138
7.
Johnson S R (1987) The epidemiology and social impact of premenstrual symptoms. Clin Obstet30: 369–384
8.
Kaplan H I, Sadock B J (2000) Kaplan and Sadock's comprehensive text book of psychiatry, 7th edn.Lippincott Williams and Wilkins, Philadelphia
9.
Logue C M, Moos R H (1986) Perimenstrual symptoms: prevalence and risk factors. Psychosom Med48: 388–414
10.
Ramcharan S, Love E J, Fick G H, Goldfien A (1992) The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol45: 377–392
11.
Rapkin A J, Edelmuth E, Chang L C, Reading A E, McGuire M T, Su T P (1987) Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol70: 533–537
12.
Rapkin A J, Reading A E, Woo S, Goldman L M (1991) Tryptophan and neutral amino acids in premenstrual syndrome. Am J Obstet Gynecol165: 1830–1833
13.
Rivera-Tovar A D, Frank E (1990) Late luteal phase dysphoric disorder in young women. Am J Psychiatry147: 1634–1636
14.
Rojansky N, Halbreich U, Zamker K, Barkai A, Goldstein S (1991) Imipramine receptors binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest31: 146–152
15.
Rubinow D R, Schmidt P J, Roca C A (1998) Estrogen– serotonin interactions: implications for affective regulation. Biol Psychiatry44: 839–850
16.
Stahl S M, Frakes D C (1995) Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. Int Rev Psychiatry7: 29–39
17.
Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, et al. (1995) Fluoxetine in the treatment of premenstrual dysphoria. N Eng J Med23: 1529–1534
18.
Steinberg S, Annable L, Young S N, Liyanage N (1999) A placebocontrolled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry45: 313–320
19.
Sundlad C, Hedberg M A, Eriksson E (1993) Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology9: 133–145
20.
Sveindottir H, Backstrom T (2000) Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand79: 405–413
21.
Taylor D L, Matthew R J, Ho B T, Wienman M L (1984) Serotonin levels and platelet uptake during premenstrual tension. Neuropsychology12: 16–18
22.
Woods N F, Most A, Dery G K, et al. (1982) Prevalence of perimenstrual symptoms. Am J Public Health72: 1257–1264
23.
Yatham L, Barry S, Dina T G (1989) Serotonin receptors, buspirone and premenstrual syndrome. Lancet1: 1447–1448
24.
Yonkers K A, Gullion C, Williams A, Novak K, Rush A J (1996) Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol16: 3–8
25.
Yonkers K A, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, et al. (1997) Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA12: 983–988
